arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Lineage Cell Therapeutics, Inc.

LCTX
$0.97 ▼ -0.06 (-5.46%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
68 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
7
Health
Poor
Bearish
auto_awesome

Analytical Summary

Lineage Cell Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $242.0M
Dividend Yield —
Revenue Growth -61.3% ↘
Op. Margin None
ROIC -11.6% ↘
FCF / Share $-0.03 ↗
Trailing P/E 97.0x
Price / Book 4.0x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

68-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.07M
↓ -61.3% —
Net Income Profit after all expenses
$1.48M
↑ +130.8% —
Operating Margin Operating profit as % of sales
-440.2%
↓ -344.2% 0th
FCF / Share Free cash flow per share
$-0.03
↑ +11.2% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
1
Returns ↓
5
Financial Health ↑
4
Cash Quality ↓
33

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 18 years · 68 quarters